Price £134 + VAT per dose
We stock BOTH the approved vaccines - Vaccine 1 for ages 9-26 and Vaccine 2 for ages 10-55 years
Safety of Cervical Cancer Vaccines
We will consider the off-license use in men or boys after a suitable consultation
The vaccines are available for the prevention of cervical cancer in females and genital warts in both males and females. One vaccine can be given to females aged between 9 and 26 and males aged between 9 to 15 years. The other vaccine can be given to women age 10-55 years. The cost of the vaccine is £134 + VAT per dose and three doses are required over a period of time to acquire immunity.
The USA
The Centers for Disease Control and Prevention estimates that about 6.2 million Americans become infected with genital HPV each year and that over half of all sexually active men and women become infected at some time in their lives. On average, there are 9,710 new cases of cervical cancer and 3,700 deaths attributed to it in the United States each year. Worldwide, cervical cancer is the second most common cancer in women; and is estimated to cause over 470,000 new cases and 233,000 deaths each year.
'Young girls in Germany are to be vaccinated against the virus that causes cervical cancer.
Italian health officials have also recommended 12-year old girls are immunised against human papillomavirus. '
More
>>
The UK
Information from the Health Protection Agency is available at:
http://www.hpa.org.uk/infections/topics_az/hiv_and_sti/sti-warts/warts.htm
The Patient Information leaflet is available at:
http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?
DocumentID=19033
For most women, the body's own defence system will clear the virus and infected women do not develop related health problems. However, some HPV types can cause abnormal cells on the lining of the cervix that years later can turn into cancer. Other HPV types can cause genital warts. The vaccine is effective against HPV types 16 and 18, which cause approximately 70 percent of cervical cancers and against HPV types 6 and 11, which cause approximately 90 percent of genital warts.
The vaccine is a recombinant vaccine (contains no live virus) that is given as three injections over a six-month period. Immunization with The vaccine is expected to prevent most cases of cervical cancer due to HPV types included in the vaccine. However, females are not protected if they have been infected with that HPV type(s) prior to vaccination, indicating the importance of immunization before potential exposure to the virus. Also, The vaccine does not protect against less common HPV types not included in the vaccine, thus routine and regular pap screening remain critically important to detect precancerous changes in the cervix to allow treatment before cervical cancer develops.
Four studies, one in the United States and three multinational, were conducted in 21,000 women to show how well The vaccine worked in women between the ages of 16 and 26 by giving them either the vaccine or placebo. The results showed that in women who had not already been infected, the vaccine was nearly 100 percent effective in preventing precancerous cervical lesions, precancerous vaginal and vulvar lesions, and genital warts caused by infection with the HPV types against which the vaccine is directed. While the study period was not long enough for cervical cancer to develop, the prevention of these cervical precancerous lesions is believed highly likely to result in the prevention of those cancers.
The studies also evaluated whether the vaccine can protect women already infected with some HPV types included in the vaccine from developing diseases related to those viruses. The results show that the vaccine is only effective when given prior to infection.
Two studies were also performed to measure the immune response to the vaccine among younger females aged 9-15 years. Their immune response was as good as that found in 16-26 year olds, indicating that the vaccine should have similar effectiveness when used in the 9-15 year age group.
The safety of the vaccine was evaluated in approximately 11,000 individuals. Most adverse experiences in study participants who received the vaccine included mild or moderate local reactions, such as pain or tenderness at the site of injection.
The manufacturer has agreed to conduct several studies following licensure, including additional studies to further evaluate general safety and long-term effectiveness. The manufacturer will also monitor the pregnancy outcomes of women who receive the vaccine while unknowingly pregnant. Also, the manufacturer has an ongoing study to evaluate the safety and effectiveness of the vaccine in males.
<< Back
Certification Number EO10000521
